Welcome to the next episode of our CEO Chat series. My name is David Bautz, and I'm a senior biotechnology analyst here at Zacks Small Cap Research . Joining me today is Mr. Jared Kelly. He's the CEO ...

Three of the top four ASX biotechs are facing a harsh reality check as investors question the ‘stronger for longer’ mentality ...

With an IPO raise of $625 million, Kailera Therapeutics now holds the new record for the largest public market debut.

AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering next-generation gene therapies for inherited ...

New Jersey's Johnson & Johnson grew from one ambitious pharmacist to a $94 billion pharmaceutical and medical device giant.

Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, according to The Information and Eric Newcomer. Sources close to the deal confirmed to TechCrunch ...

Biotech has benefited marginally from this rotation. Value beat growth notably in the first quarter. The energy sector was obviously the best performing of the 11 sectors of the S&P 500 in Q1 with a ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...

State Street SPDR S&P Biotech ETF (XBI) gained +40.32% over the past year and equally weights roughly 145 stocks to provide exposure to smaller biotech companies. iShares Biotechnology ETF (IBB) ...

Excalipoint Therapeutics Inc. launched with an oversubscribed $68.7 million seed financing round to advance a portfolio of T-cell engagers for solid tumors, marking one of the largest early stage ...